Calcipotriol
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
- Calcipotriol
- Pharmacist Assessment Report
- Calcipotriol: From Psoriasis (Topical Vitamin D3 Analogue) to Seborrheic Keratosis
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Calcipotriol: From Psoriasis (Topical Vitamin D3 Analogue) to Seborrheic Keratosis
One-Sentence Summary
Calcipotriol is a topical vitamin D3 analogue that is widely marketed in India in ointment and lotion products. The approved indication text is not recorded in the data compiled for this report. The TxGNN model predicts it may be effective for seborrheic keratosis, supported by no registered clinical trials and 4 publications, which are mostly small case-level or uncontrolled clinical reports.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the licence records (calcipotriol is generally known as a psoriasis treatment) |
| Predicted New Indication | Seborrheic keratosis |
| TxGNN Prediction Score | 0.9996 |
| Evidence Level | L3 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold (treat as a research question) |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Based on known pharmacology, calcipotriol is a vitamin D3 analogue that binds the vitamin D receptor in keratinocytes. This inhibits cell proliferation, promotes differentiation and can induce apoptosis. These are the effects that make it useful in psoriasis, a disease of excessive keratinocyte growth.
Seborrheic keratosis is a common, benign, slow-growing epidermal tumour of keratinocytes, mostly in older adults. Because both conditions involve excess keratinocyte proliferation, a mechanistic link is plausible. Japanese reports on topical active vitamin D3 in “senile warts” (an older term for seborrheic keratosis) suggest apoptosis induction as a possible mechanism.
The evidence is still preliminary. The available reports are small and uncontrolled, and no randomized trial has been identified.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36752725 | 2023 | Case series (12 patients) | Australas J Dermatol | 0.005% calcipotriol ointment for 3–8 months on facial flat seborrheic keratosis; complete regression of lesions, with remission lasting 6–10 years |
| 16043912 | 2005 | Clinical/mechanistic study | J Dermatol | Topical vitamin D3 analogues (tacalcitol, calcipotriol, maxacalcitol) in 116 senile wart cases treated for 3–12 months; 35 cases (30.2%) responded; apoptosis induction proposed as the mechanism |
| 15577148 | 2004 | Clinical report/review | Clin Calcium | Overview of active vitamin D3 ointments for senile warts as an alternative to surgery, freezing or laser |
| 10721662 | 2000 | Case report | J Dermatol | Marked response of keratosis lichenoides chronica (a different keratotic disorder) to calcipotriol ointment; indirect relevance only |
India Market Information
Twenty valid single-ingredient registrations exist, with no cancelled or combination licences. The approved indication text is not recorded for any of them. Main examples:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 37343 | Covate-C Ointment (Canbro Healthcare) | Ointment, 20 g tube | Not recorded |
| 201404 | Soristop-C Lotion (Alniche Life Sciences) | Lotion, 30 ml bottle | Not recorded |
| 173902 | Pasitrex Ointment (Sun Pharmaceutical) | Ointment, 20 g tube | Not recorded |
| 35800 | Calpsor Ointment (Biocon) | Ointment, 30 g tube | Not recorded |
| 34929 | Calpsor C Lotion (Biocon) | Lotion, 20 ml bottle | Not recorded |
All products are topical ointments or lotions.
Safety Considerations
- Drug Interactions: The interaction screen returned 84 records. The 20 displayed have no severity grading. They include corticosteroids (triamcinolone, prednisone, prednisolone, hydrocortisone), proton pump inhibitors (omeprazole, pantoprazole, lansoprazole, rabeprazole), doxycycline, clarithromycin, metformin and simvastatin. Their clinical significance is unclear for topical use.
- Knowledge-graph contraindication signals (from disease-drug links, not label text): hypercalcemia and other calcium metabolism disorders, nephrocalcinosis, hypervitaminosis, adrenocortical insufficiency, skin atrophy, telangiectasis, peripheral vascular disease, calciphylaxis and calcinosis. Also listed are several ichthyoses, Darier disease, pseudoxanthoma elasticum and guttate psoriasis.
Package insert warnings and contraindications were not available. Please refer to the package insert for authoritative safety information.
Conclusion and Next Steps
Decision: Hold (research question)
Rationale: The prediction score is very high and there is a plausible keratinocyte-based mechanism. However, the supporting evidence consists of small uncontrolled studies and case series, with no registered trials and no randomized comparison. The package insert safety data and approved indications are also missing, so safety screening cannot yet proceed.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Indian product labels
- Approved indication text for the Indian licences
- Detailed mechanism of action data
- A controlled study (for example, randomized versus standard treatments such as cryotherapy) in seborrheic keratosis
- A calcium and skin safety monitoring plan, given the hypercalcemia and skin atrophy signals
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.